2020 Q1 Form 10-Q Financial Statement
#000156459020022861 Filed on May 07, 2020
Income Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| Revenue | $0.00 | $0.00 |
| YoY Change | ||
| Cost Of Revenue | ||
| YoY Change | ||
| Gross Profit | ||
| YoY Change | ||
| Gross Profit Margin | ||
| Selling, General & Admin | $5.950M | $4.480M |
| YoY Change | 32.81% | 29.48% |
| % of Gross Profit | ||
| Research & Development | $19.27M | $16.51M |
| YoY Change | 16.72% | 26.72% |
| % of Gross Profit | ||
| Depreciation & Amortization | $903.0K | $637.0K |
| YoY Change | 41.76% | 26.89% |
| % of Gross Profit | ||
| Operating Expenses | $27.16M | $19.74M |
| YoY Change | 37.59% | 19.75% |
| Operating Profit | -$27.16M | -$19.74M |
| YoY Change | 37.59% | 19.75% |
| Interest Expense | $0.00 | $1.006M |
| YoY Change | -100.0% | 185.8% |
| % of Operating Profit | ||
| Other Income/Expense, Net | -$1.409M | -$36.00K |
| YoY Change | 3813.89% | |
| Pretax Income | -$28.04M | -$18.77M |
| YoY Change | 49.39% | 16.37% |
| Income Tax | ||
| % Of Pretax Income | ||
| Net Earnings | -$28.04M | -$18.77M |
| YoY Change | 49.4% | 16.33% |
| Net Earnings / Revenue | ||
| Basic Earnings Per Share | ||
| Diluted Earnings Per Share | -$5.90 | -$4.45 |
| COMMON SHARES | ||
| Basic Shares Outstanding | ||
| Diluted Shares Outstanding |
Balance Sheet
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| SHORT-TERM ASSETS | ||
| Cash & Short-Term Investments | $113.4M | $150.2M |
| YoY Change | -24.5% | 12.09% |
| Cash & Equivalents | $26.51M | $35.70M |
| Short-Term Investments | $88.30M | $115.9M |
| Other Short-Term Assets | $1.900M | $1.600M |
| YoY Change | 18.75% | -33.33% |
| Inventory | ||
| Prepaid Expenses | ||
| Receivables | ||
| Other Receivables | ||
| Total Short-Term Assets | $115.2M | $151.8M |
| YoY Change | -24.11% | 11.26% |
| LONG-TERM ASSETS | ||
| Property, Plant & Equipment | $40.50M | $5.900M |
| YoY Change | 586.44% | -10.48% |
| Goodwill | ||
| YoY Change | ||
| Intangibles | ||
| YoY Change | ||
| Long-Term Investments | $0.00 | |
| YoY Change | ||
| Other Assets | $2.000M | $3.100M |
| YoY Change | -35.48% | 493.87% |
| Total Long-Term Assets | $42.60M | $9.000M |
| YoY Change | 373.33% | 17.45% |
| TOTAL ASSETS | ||
| Total Short-Term Assets | $115.2M | $151.8M |
| Total Long-Term Assets | $42.60M | $9.000M |
| Total Assets | $157.8M | $160.8M |
| YoY Change | -1.87% | 11.59% |
| SHORT-TERM LIABILITIES | ||
| YoY Change | ||
| Accounts Payable | $4.000M | $4.100M |
| YoY Change | -2.44% | -18.6% |
| Accrued Expenses | $9.600M | $6.600M |
| YoY Change | 45.45% | 17.86% |
| Deferred Revenue | ||
| YoY Change | ||
| Short-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Long-Term Debt Due | ||
| YoY Change | ||
| Total Short-Term Liabilities | $14.60M | $11.11M |
| YoY Change | 31.4% | 4.2% |
| LONG-TERM LIABILITIES | ||
| Long-Term Debt | $0.00 | $0.00 |
| YoY Change | ||
| Other Long-Term Liabilities | $37.90M | $3.100M |
| YoY Change | 1122.58% | 2969.31% |
| Total Long-Term Liabilities | $37.90M | $3.100M |
| YoY Change | 1122.58% | 2969.31% |
| TOTAL LIABILITIES | ||
| Total Short-Term Liabilities | $14.60M | $11.11M |
| Total Long-Term Liabilities | $37.90M | $3.100M |
| Total Liabilities | $52.50M | $14.20M |
| YoY Change | 269.72% | 2.71% |
| SHAREHOLDERS EQUITY | ||
| Retained Earnings | ||
| YoY Change | ||
| Common Stock | $329.2M | |
| YoY Change | 32922900.0% | |
| Preferred Stock | ||
| YoY Change | ||
| Treasury Stock (at cost) | ||
| YoY Change | ||
| Treasury Stock Shares | ||
| Shareholders Equity | $105.3M | $146.6M |
| YoY Change | ||
| Total Liabilities & Shareholders Equity | $157.8M | $160.8M |
| YoY Change | -1.87% | 11.59% |
Cashflow Statement
| Concept | 2020 Q1 | 2019 Q1 |
|---|---|---|
| OPERATING ACTIVITIES | ||
| Net Income | -$28.04M | -$18.77M |
| YoY Change | 49.4% | 16.33% |
| Depreciation, Depletion And Amortization | $903.0K | $637.0K |
| YoY Change | 41.76% | 26.89% |
| Cash From Operating Activities | -$25.10M | -$20.60M |
| YoY Change | 21.87% | 73.32% |
| INVESTING ACTIVITIES | ||
| Capital Expenditures | $34.00K | $207.0K |
| YoY Change | -83.57% | 104.95% |
| Acquisitions | ||
| YoY Change | ||
| Other Investing Activities | $3.700M | $40.27M |
| YoY Change | -90.81% | 208.58% |
| Cash From Investing Activities | $3.666M | $40.06M |
| YoY Change | -90.85% | 209.42% |
| FINANCING ACTIVITIES | ||
| Cash Dividend Paid | ||
| YoY Change | ||
| Common Stock Issuance & Retirement, Net | $8.763M | |
| YoY Change | ||
| Debt Paid & Issued, Net | ||
| YoY Change | ||
| Cash From Financing Activities | 8.993M | 282.0K |
| YoY Change | 3089.01% | -99.48% |
| NET CHANGE | ||
| Cash From Operating Activities | -25.10M | -20.60M |
| Cash From Investing Activities | 3.666M | 40.06M |
| Cash From Financing Activities | 8.993M | 282.0K |
| Net Change In Cash | -12.41M | 19.75M |
| YoY Change | -162.87% | -64.39% |
| FREE CASH FLOW | ||
| Cash From Operating Activities | -$25.10M | -$20.60M |
| Capital Expenditures | $34.00K | $207.0K |
| Free Cash Flow | -$25.13M | -$20.80M |
| YoY Change | 20.82% | 73.59% |
Facts In Submission
| Frame | Concept Type | Concept / XBRL Key | Value | Unit |
|---|---|---|---|---|
| CY2019Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-18767000 | |
| CY2020Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-27156000 | |
| CY2020Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
527000 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
|
P9Y | |
| CY2020Q1 | dei |
Entity Address City Or Town
EntityAddressCityOrTown
|
South San Francisco | |
| CY2020Q1 | dei |
Entity Address State Or Province
EntityAddressStateOrProvince
|
CA | |
| CY2020Q1 | dei |
Entity Address Postal Zip Code
EntityAddressPostalZipCode
|
94080 | |
| CY2020Q1 | dei |
City Area Code
CityAreaCode
|
650 | |
| CY2020Q1 | dei |
Local Phone Number
LocalPhoneNumber
|
416-1192 | |
| CY2020Q1 | dei |
Security12b Title
Security12bTitle
|
Common Stock, par value $0.0001 | |
| CY2020Q1 | dei |
Trading Symbol
TradingSymbol
|
UBX | |
| CY2020Q1 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q4 | us-gaap |
Commitments And Contingencies
CommitmentsAndContingencies
|
||
| CY2019Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
4477000 | |
| CY2020Q1 | us-gaap |
General And Administrative Expense
GeneralAndAdministrativeExpense
|
5953000 | |
| CY2019Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
1997000 | |
| CY2019Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
19737000 | |
| CY2020Q1 | ubx |
Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
|
-221000 | |
| CY2020Q1 | us-gaap |
Operating Expenses
OperatingExpenses
|
27156000 | |
| CY2019Q1 | ubx |
Change In Fair Value Of Contingent Consideration For License Agreements
ChangeInFairValueOfContingentConsiderationForLicenseAgreements
|
-1245000 | |
| CY2020Q1 | us-gaap |
Impairment Of Long Lived Assets Held For Use
ImpairmentOfLongLivedAssetsHeldForUse
|
2159000 | |
| CY2019Q1 | us-gaap |
Operating Income Loss
OperatingIncomeLoss
|
-19737000 | |
| CY2019Q1 | us-gaap |
Interest Income Expense Nonoperating Net
InterestIncomeExpenseNonoperatingNet
|
1006000 | |
| CY2020Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-1409000 | |
| CY2019Q1 | us-gaap |
Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
|
-36000 | |
| CY2020Q1 | us-gaap |
Net Income Loss
NetIncomeLoss
|
-28038000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
283000 | |
| CY2019Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
|
114000 | |
| CY2020Q1 | us-gaap |
Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
|
-0.59 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
249000 | |
| CY2020Q1 | ubx |
Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
|
40000 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Value Issued For Services
StockIssuedDuringPeriodValueIssuedForServices
|
100000 | |
| CY2018Q4 | us-gaap |
Stockholders Equity
StockholdersEquity
|
160693000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
|
300000 | |
| CY2019Q1 | ubx |
Vesting Of Early Exercised Options
VestingOfEarlyExercisedOptions
|
207000 | |
| CY2019Q1 | us-gaap |
Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
|
2059000 | |
| CY2020Q1 | us-gaap |
Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
|
3225000 | |
| CY2020Q1 | us-gaap |
Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Before Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodBeforeTax
|
283000 | |
| CY2019Q1 | us-gaap |
Stockholders Equity
StockholdersEquity
|
146603000 | |
| CY2020Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
903000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
65000 | |
| CY2020Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
3317000 | |
| CY2019Q1 | us-gaap |
Share Based Compensation
ShareBasedCompensation
|
1997000 | |
| CY2019Q1 | us-gaap |
Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
|
637000 | |
| CY2020Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
63000 | |
| CY2019Q1 | us-gaap |
Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
|
366000 | |
| CY2020Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
461000 | |
| CY2020Q1 | us-gaap |
Equity Securities Fv Ni Gain Loss
EquitySecuritiesFvNiGainLoss
|
-1387000 | |
| CY2019Q1 | ubx |
Accretion Of Tenant Improvement Allowance
AccretionOfTenantImprovementAllowance
|
152000 | |
| CY2020Q1 | ubx |
Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
|
-221000 | |
| CY2019Q1 | ubx |
Change In Fair Value Of Contingent Consideration
ChangeInFairValueOfContingentConsideration
|
-1245000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-123000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
|
-188000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
-29000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
|
9000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-1345000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
|
-776000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-3675000 | |
| CY2019Q1 | us-gaap |
Increase Decrease In Employee Related Liabilities
IncreaseDecreaseInEmployeeRelatedLiabilities
|
-2117000 | |
| CY2020Q1 | us-gaap |
Increase Decrease In Accrued Liabilities And Other Operating Liabilities
IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
|
-110000 | |
| CY2019Q1 | ubx |
Increase Decrease In Deferred Rent
IncreaseDecreaseInDeferredRent
|
-51000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-25073000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
|
-20596000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
36950000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Marketable Securities
PaymentsToAcquireMarketableSecurities
|
18054000 | |
| CY2020Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
40650000 | |
| CY2019Q1 | us-gaap |
Proceeds From Sale And Maturity Of Marketable Securities
ProceedsFromSaleAndMaturityOfMarketableSecurities
|
58321000 | |
| CY2020Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
34000 | |
| CY2019Q1 | us-gaap |
Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
|
207000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
3666000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
|
40060000 | |
| CY2020Q1 | us-gaap |
Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
|
8763000 | |
| CY2020Q1 | ubx |
Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
|
249000 | |
| CY2019Q1 | ubx |
Proceeds From Issuance Of Common Stock Upon Exercise Of Stock Options Net Of Repurchase Payments
ProceedsFromIssuanceOfCommonStockUponExerciseOfStockOptionsNetOfRepurchasePayments
|
300000 | |
| CY2020Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-19000 | |
| CY2019Q1 | us-gaap |
Proceeds From Payments For Other Financing Activities
ProceedsFromPaymentsForOtherFinancingActivities
|
-18000 | |
| CY2020Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
8993000 | |
| CY2019Q1 | us-gaap |
Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
|
282000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
-12414000 | |
| CY2019Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
71000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
|
19746000 | |
| CY2019Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
38919000 | |
| CY2018Q4 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
15949000 | |
| CY2020Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
26505000 | |
| CY2019Q1 | us-gaap |
Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents
|
35695000 | |
| CY2020Q1 | us-gaap |
Capital Expenditures Incurred But Not Yet Paid
CapitalExpendituresIncurredButNotYetPaid
|
302000 | |
| CY2020Q1 | ubx |
Issuance Of Shares In Settlement Of Share Based Liability
IssuanceOfSharesInSettlementOfShareBasedLiability
|
100000 | |
| CY2019Q1 | us-gaap |
Stock Issued1
StockIssued1
|
2059000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
|
54970000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
|
12763000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability
OperatingLeaseLiability
|
42207000 | |
| CY2020Q1 | us-gaap |
Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
|
4318000 | |
| CY2019Q2 | ubx |
Sale Of Equity Financing Authorized Amount
SaleOfEquityFinancingAuthorizedAmount
|
250000000 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
6906898 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
|
2903256 | |
| CY2020Q1 | us-gaap |
Stock Issued During Period Shares Stock Options Exercised
StockIssuedDuringPeriodSharesStockOptionsExercised
|
73049 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod
|
216345 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber
|
9520760 | |
| CY2019Q4 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.62 | |
| CY2020Q1 | ubx |
Share Based Compensation Arrangement By Share Based Payment Number Of Shares Issued In Settlement Of Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentNumberOfSharesIssuedInSettlementOfLiabilityAward
|
13550 | |
| CY2020Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
3317000 | |
| CY2020Q1 | us-gaap |
Use Of Estimates
UseOfEstimates
|
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Use of Estimates</p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The condensed financial statements have been prepared in accordance with GAAP, which requires management to make estimates and assumptions that affect the amounts and disclosures reported in the condensed financial statements and accompanying notes. The Company bases its estimates on historical experience and market-specific or other relevant assumptions that it believes are reasonable under the circumstances. The amounts of assets and liabilities reported in the Company’s condensed balance sheets and the amount of expenses and income reported for each of the periods presented are affected by estimates and assumptions, which are used for, but are not limited to, determining the fair value of assets and liabilities, contingent consideration liability and stock-based compensation. Actual results could differ from such estimates or assumptions.</p> | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk
ConcentrationRiskCreditRisk
|
<p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-weight:bold;font-size:10pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Concentrations of Risk </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financial instruments that potentially subject the Company to significant concentrations of credit risk consist primarily of cash, cash equivalents, restricted cash and marketable securities. Substantially all of the Company’s cash and cash equivalents and restricted cash is deposited in accounts with financial institutions that management believes are of high credit quality. Such deposits have and will continue to exceed federally insured limits. The Company maintains its cash with accredited financial institutions and accordingly, such funds are subject to minimal credit risk. The Company has not experienced any losses on its cash deposits. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company’s investment policy limits investments to certain types of securities issued by the U.S. government, its agencies and institutions with investment-grade credit ratings and places restrictions on maturities and concentration by type and issuer. The Company is exposed to credit risk in the event of a default by the financial institutions holding its cash, cash equivalents, restricted cash and marketable securities and issuers of marketable securities to the extent recorded on the balance sheets. As of March 31, 2020, the Company had no off-balance sheet concentrations of credit risk. </p> <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is also exposed to market risk in its strategic investments. As of March 31, 2020, the Company held an investment in common stock which is publicly traded.</p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company depends on third-party suppliers for key raw materials used in its manufacturing processes and is subject to certain risks related to the loss of these third-party suppliers or their inability to supply the Company with adequate raw materials. </p> <p style="margin-bottom:0pt;margin-top:12pt;text-align:justify;text-indent:0%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In March 2020 the World Health Organization declared the global novel coronavirus (“COVID-19”) outbreak a pandemic. To date, the Company’s operations have not been significantly impacted by the COVID-19 pandemic. However, the Company cannot at this time predict the specific extent, duration, or full impact that the COVID-19 pandemic will have on its financial condition and results of operations, including ongoing and planned clinical studies. The impact of the COVID-19 pandemic on the financial performance of the Company will depend on future developments, including the duration and spread of the COVID-19 pandemic and related governmental advisories and restrictions. These developments and the impact of COVID-19 on the financial markets and the overall economy are highly uncertain. If the financial markets and/or the overall economy are impacted for an extended period, the Company’s business, financial condition, results of operations and prospects may be adversely affected. </p> | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice
|
6.05 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice
|
3.41 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriodWeightedAverageExercisePrice
|
10.88 | |
| CY2020Q1 | us-gaap |
Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price
ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
|
7.10 | |
| CY2020Q1 | us-gaap |
Sharebased Compensation Arrangement By Sharebased Payment Award Compensation Cost1
SharebasedCompensationArrangementBySharebasedPaymentAwardCompensationCost1
|
200000 | |
| CY2019Q1 | us-gaap |
Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
|
1997000 | |
| CY2020Q1 | ubx |
Share Based Compensation Arrangement By Share Based Payment Expense Related To Liability Award
ShareBasedCompensationArrangementByShareBasedPaymentExpenseRelatedToLiabilityAward
|
100000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due After Year Five
LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFive
|
27302000 | |
| CY2020Q1 | us-gaap |
Number Of Operating Segments
NumberOfOperatingSegments
|
1 | |
| CY2020Q1 | ubx |
Cash Cash Equivalents And Marketable Securities
CashCashEquivalentsAndMarketableSecurities
|
109200000 | |
| CY2020Q1 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
1446000 | |
| CY2019Q4 | us-gaap |
Restricted Cash And Cash Equivalents
RestrictedCashAndCashEquivalents
|
1446000 | |
| CY2020Q1 | us-gaap |
Concentration Risk Credit Risk Financial Instruments Off Balance Sheet Risk
ConcentrationRiskCreditRiskFinancialInstrumentsOffBalanceSheetRisk
|
As of March 31, 2020, the Company had no off-balance sheet concentrations of credit risk. | |
| CY2020Q1 | ubx |
Concentration Risk Credit Risk Off Balance Sheet Risk
ConcentrationRiskCreditRiskOffBalanceSheetRisk
|
0 | |
| CY2020Q1 | us-gaap |
Lessee Finance Lease Term Of Contract1
LesseeFinanceLeaseTermOfContract1
|
P3Y | |
| CY2020Q1 | us-gaap |
Impairment Of Leasehold
ImpairmentOfLeasehold
|
2200000 | |
| CY2020Q1 | ubx |
Percentage Of Cumulative Probability Of Defined Milestones
PercentageOfCumulativeProbabilityOfDefinedMilestones
|
0.675 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
108864000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
396000 | |
| CY2020Q1 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
22000 | |
| CY2020Q1 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
109238000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Amortized Cost Basis
AvailableForSaleDebtSecuritiesAmortizedCostBasis
|
124368000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
|
92000 | |
| CY2019Q4 | us-gaap |
Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
|
1000 | |
| CY2019Q4 | us-gaap |
Available For Sale Securities Debt Securities
AvailableForSaleSecuritiesDebtSecurities
|
124459000 | |
| CY2020Q1 | us-gaap |
Debt Securities Available For Sale Realized Gain Loss
DebtSecuritiesAvailableForSaleRealizedGainLoss
|
0 | |
| CY2020Q1 | ubx |
Compound Library And Option Agreement Execution Month And Year
CompoundLibraryAndOptionAgreementExecutionMonthAndYear
|
2016-02 | |
| CY2020Q1 | us-gaap |
Operating Lease Cost
OperatingLeaseCost
|
1300000 | |
| CY2020Q1 | us-gaap |
Variable Lease Cost
VariableLeaseCost
|
278000 | |
| CY2020Q1 | ubx |
Impairment Of Operating Lease Right Of Use Asset
ImpairmentOfOperatingLeaseRightOfUseAsset
|
1157000 | |
| CY2019Q1 | us-gaap |
Operating Lease Expense
OperatingLeaseExpense
|
400000 | |
| CY2020Q1 | us-gaap |
Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
|
0.058 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Remainder Of Fiscal Year
LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear
|
4958000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
|
6653000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
|
6283000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
|
4810000 | |
| CY2020Q1 | us-gaap |
Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
|
4964000 | |
| CY2020Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
10657825 | |
| CY2019Q1 | us-gaap |
Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
|
5994009 |
